<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839176</url>
  </required_header>
  <id_info>
    <org_study_id>RX-10100-P2A-002</org_study_id>
    <nct_id>NCT00839176</nct_id>
  </id_info>
  <brief_title>Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)</brief_title>
  <official_title>A Double-blinded, Randomized, Placebo-controlled, Dose-Exploring Study of RX-10100 When Given for Eight Consecutive Weeks to Subjects With Major Depression Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rexahn Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rexahn Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this Phase IIa trial is to determine the effective dose and
      treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression
      disorder (MDD). The secondary objectives of this trial are to evaluate the safety and quality
      of life in subjects with MDD receiving RX-10100 treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline at 8 weeks on the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on the HAM-D</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on the QIDS-SR</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I scale at the end of treatment,</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects during and immediately following the treatment period</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (w/o API)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg dose of RX-10100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg dose of RX-10100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg dose of RX-10100</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10100</intervention_name>
    <description>Extended-release tablet, 5~15mg, twice day (morning &amp; evening) at least 30 min before meal, 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Serdaxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 18 and 65 years old

          -  Diagnosis of MDD using DSM-IV criteria

          -  Have a score of 20 or more on the HAM-D-17

          -  Have a score of 4 or more on the CGI-S

          -  Written informed consent obtained

          -  Have a negative serum (P-HCG) pregnancy test at screening (for all women)

          -  Female subjects must meet one of the following criteria: (a) Be surgically sterile or
             (b) Agree that, if sexually active they will use oral contraceptives, double barrier
             contraception (E.g., condom with spermicide), intrauterine device, or other method
             approved by the sponsor.

        Exclusion Criteria:

          -  Have a BMI &gt; 40 or &lt; 18

          -  Unstable angina pectoris

          -  History of myocardial infarction, stroke, or life-threatening arrhythmia within the
             prior 6 months

          -  Uncontrolled atrial fibrillation/flutter at screening

          -  Severe chronic or acute liver disease; history of moderate or severe hepatic
             impairment

          -  Clinically significant chronic hematological disease which may lead to priapism, such
             as sickle cell anemia and leukemia

          -  Bleeding disorder

          -  Resting hypotension or hypertension

          -  History of malignancy (cancers) within the past 5 years (other than squamous or basal
             cell skin cancer)

          -  NYHA Class III or IV heart failure

          -  Substance abuse/dependence within the past 6 months

          -  Significant suicidal ideation based on the C-SSRS

          -  Other current nondepressive Axis I disorders

          -  Depressive episode duration of less than 1 month or greater than 9 months

          -  Bipolar disorder

          -  Dysthmic disorder

          -  Borderline personality disorder

          -  Psychotic disorder/current psychotic features

          -  Any abnormal findings on the screening ECG judged clinically significant by the
             Investigator

          -  Any medical condition that is not stabilized or is anticipated to require
             hospitalization within 6 months, in the opinion of the Investigator

          -  Any history of cholestatic jaundice or liver cirrhosis

          -  Hyper- or hypothyroidism unless the subject has received a stable dose of thyroid
             medication for at least 3 months prior to the screening visit

          -  Women, who are breast-feeding, have been lactating within 3 months prior to screening

          -  Concurrent psychotherapy

          -  Subjects who have received any other investigational drug (including placebo) within
             30 days before Visit 1

          -  Use of any treatment for MDD within 7 days of Visit 1 (14 days for fluoxetine) and
             during the study other than the study medication

          -  Use of antidepressants, anxiolytics, or other psychoactive drugs within 14 days of
             Visit 1 and during the study

          -  Concomitant use of antibiotics in the penicillin class (for the reduction of the
             potential for any additive or synergistic hepatotoxicity)

          -  A positive urine drug screen

          -  Elevation of AST and/or ALT &gt; 3 times the upper limit of normal (ULN)

          -  Diabetic subjects with an HbAlc â‰¥ 12%

          -  Any abnormal screening laboratory values judged clinically significant by the
             Investigator

          -  Previous nonresponse or hypersensitivity to two or more trials of antidepressant
             medication given in adequate doses and duration for the treatment of symptoms present
             in the current illness

          -  Subjects with known hypersensitivity to any antibiotic in the penicillin class

          -  Subjects who are illiterate or unable to understand the questionnaires

          -  Subjects who, in the opinion of the investigator, would be non-compliant with the
             visit schedule of study procedures

          -  Subjects who pose potential harm to others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Peterson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rexahn Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder (MDD)</keyword>
  <keyword>Serdaxin</keyword>
  <keyword>Rexahn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

